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a  b  s  t  r  a  c  t
Osteoarthritis  (OA)  is  a  whole  joint  disease  characterized  by  cartilage  degradation,  which  causes  pain
and disability  in  older  adults.  Our  previous  work  showed  that  growth  arrest  and  DNA  damage-inducible
protein  45  (GADD45)  is  upregulated  in chondrocyte  clusters  in  OA cartilage,  especially  in the early
stage  of  this  disease.  CCAAT/enhancer  binding  protein   (C/EBP)  is  expressed  in  the  hypertrophic
growth  plate  chondrocytes  and  functions  in synergy  with  GADD45.  Here,  the presence  and  localiza-
tion  of  these  proteins  was  assessed  by immunohistochemistry  using  articular  cartilage  from  OA  patients,
revealing  colocalization  of  C/EBP  and  GADD45  in  OA  chondrocytes.  GADD45ˇ  promoter  analysis  was
performed  to determine  whether  C/EBP  directly  regulates  GADD45ˇ  transcription.  Furthermore,  we
analyzed  the  effect  of C/EBP  on  Gadd45ˇ  gene  regulation  in  articular  chondrocytes  in vivo  and  in vitro.
Immunohistochemical  analysis  of  C/ebpˇ-haploinsufﬁcient  mice  (C/ebpˇ+/−) cartilage  showed  that  C/ebpˇ
haploinsufﬁciency  led  to reduced  Gadd45ˇ  gene  expression  in  these  cells.  In  vitro,  we evaluated  the  effects
of  conditional  C/EBP  overexpression  driven  by the  cartilage  oligomeric  matrix  protein  (Comp)  promoter
in  mComp-tTA;pTRE-Tight-BI-DsRed-mC/ebp  ˇ transgenic  mice.  C/EBP  overexpression  signiﬁcantly  stim-
ulated  Gadd45ˇ  gene  expression  in articular  chondrocytes.  Taken  together,  our data  demonstrate  that
C/EBP plays  a  central  role  in  controlling  Gadd45ˇ  gene  expression  in these  cells.
thor©  2016  The  Au
ntroduction
Growth arrest and DNA damage-inducible protein 45 
GADD45) belongs to a family of 18-kD proteins that are
nduced by genotoxic stress and regulate apoptosis and chon-
rocyte differentiation by modulating stress-responsive, mitogen-
ctivated protein kinase cascades [1–5]. GADD45 is expressed in
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hypertrophic chondrocytes and plays an important role in the
terminal differentiation that leads to endochondral ossiﬁcation
[6]. Furthermore, this protein is expressed in adult articular
chondrocytes, and is upregulated in aging articular cartilage and
chondrocyte clusters in osteoarthritis (OA) cartilage, especially in
the early stage of this disease [7]. GADD45 overexpression down-
regulates expression of the type II collagen gene Col2a1,  while
upregulating type X collagen (Col10a1) and matrix metallopro-
teinase 13 (Mmp13) genes in chondrocytes [6,8]. These results
suggest that GADD45 plays an essential role in chondrocyte
homeostasis, and that its aberrant expression may  be involved in
OA pathogenesis. However, the molecular mechanisms controlling
its expression in these cells remain unknown.
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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CCAAT/enhancer binding protein  (C/EBP) is a member of the
ZIP transcription factor family and is characterized by its basic
egion and leucine zipper domain [9–14]. C/ebp  ˇ is transcribed
rom an intron-less gene that gives rise to three protein isoforms
rom a single mRNA. The two larger isoforms, liver-enriched acti-
ating protein (LAP*, i.e. full length C/EBP)  and the slightly shorter
ersion LAP, contain dimerization, DNA-binding, and negative reg-
latory domains, in addition to several transactivation domains.
AP* is produced by translation initiation at the ﬁrst in-frame AUG,
hile LAP results from translation beginning 21–23 codons down-
tream, at the second AUG of this reading frame. Initiation at the
hird AUG gives rise to the third isoform, liver-enriched inhibiting
rotein (LIP), which lacks an N-terminal transactivation domain
15].
Recent work has shown that C/EBP  is involved in regulat-
ng gene expression during hematopoiesis, adipogenesis [16–20],
nd chondrogenesis, in which this protein plays a crucial role in
he transition from proliferative to hypertrophic phenotype [21].
n the other hand, its high expression may  also contribute to
he pathogenesis of inﬂammatory arthritis [22,23] and OA [24].
onsidering that C/EBP  colocalizes with GADD45 in aged artic-
lar cartilage [25], we hypothesized the former to be a candidate
ranscriptional regulator of Gadd45  ˇ in this tissue.
In the present study, we show that C/EBP  regulates transcrip-
ion of the Gadd45  ˇ gene in articular chondrocytes in vitro and
n vivo.
aterials and methods
linical samples
Articular cartilage samples were obtained with the approval of
he institutional review board of Kagoshima University from ﬁve
atients with OA (two men  and three women aged 66 ± 14.5 years
mean ± SD]) undergoing total hip arthroplasty, and three with
emoral neck fracture or idiopathic osteonecrosis of the femoral
ead (one man  and two women aged 59.3 ± 7.6 years [mean ± SD])
ndergoing bipolar hip arthroplasty. All OA cases were classiﬁed as
eing in the advanced stage. The study protocol was  approved by
he clinical study ethics committee of Kagoshima University Med-
cal and Dental Hospital (permit number 23-2). All patients and
ontrol subjects gave written informed consent.
mmunohistochemistry
Multiple regions of cartilage (5 mm × 5 mm)  were ﬁxed in 4%
araformaldehyde for 1 day at room temperature before being
mbedded in parafﬁn. Serial 5-m thick sections were then cut
rom the parafﬁn-embedded blocks. Sections were deparafﬁnized
n xylene, rehydrated through an ethanol series, and stained
ith hematoxylin-eosin and toluidine blue. Immunohistochem-
stry was performed as described previously [26], using goat
olyclonal anti-GADD45  (C-18, catalog number sc-8776, Santa
ruz Biotechnology, Santa Cruz, CA, USA; 1:200 dilution, 0.5 g/mL
nal concentration) and rabbit polyclonal anti-C/EBP (C-19, cat-
log number sc-150, Santa Cruz Biotechnology; 1:100 dilution,
.2 g/mL ﬁnal concentration) antibodies. Rabbit biotinylated anti-
oat IgG (Sigma–Aldrich, St. Louis, MO,  USA) and a VECTASTAIN
lite ABC Kit (Vector Laboratories, Inc., Burlingame, CA, USA) were
sed for visualization. Goat or rabbit IgG (catalog numbers sc-2028
nd sc-2027, respectively, Santa Cruz Biotechnology) was used in
lace of the primary antibody as a negative control.
Colocalization of GADD45 and C/EBP  immunoreactivities
as observed using confocal laser scanning microscopy (CLSM;
odel FV500, Olympus, Tokyo, Japan). After exposure to the twoand Practice 212 (2016) 302–309 303
primary antibodies, sections were washed and incubated with
Alexa Fluor 546-conjugated anti-goat IgG (1:200 in PBS) and ﬂuo-
rescein isothiocyanate-conjugated anti-rabbit IgG (1:200 in PBS)
antibodies for 60 min. All sections were counterstained with 4′,6-
diamino-2-phenylindole (Invitrogen, Tokyo, Japan).
Cell culture
ATDC5 mouse teratocarcinoma cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM)/Ham’s F-12 (Invitrogen; 1:1,
v/v) containing 5% fetal calf serum (FCS; Biowhittaker, Walkersville,
MD,  USA), as described previously [6].
Primary chondrocytes were isolated by sequential digestion of
articular cartilage from 6-day-old mice using collagenase P (Invitro-
gen), as described by Gosset et al. [27]. Isolated chondrocytes were
then cultured to conﬂuence in DMEM/Ham’s F-12 containing 10%
FCS.
Transfection and reporter assays
In order to deﬁne the effects of C/EBP and GADD45 on tar-
get gene expression, luciferase reporter plasmids containing the
GADD45 gene promoter were transfected into ATDC5 cells in
combination with expression plasmids encoding GADD45 and
C/EBP,  alone or together. ATDC5 cells were transiently trans-
fected using Lipofectamine Plus Reagent (Invitrogen), as described
previously [6]. Brieﬂy, cells were seeded 24 h prior to transfec-
tion in 24-well tissue culture plates at a concentration of 1.0 × 105
cells/well in DMEM/Ham’s F-12 containing 5% FCS. Transfections
were performed in serum-free medium with no more than 475 ng
of plasmid DNA, including 300 ng of luciferase reporter plasmid
per well. Unless speciﬁed otherwise, luciferase activity was nor-
malized to the pRL-TK Renilla luciferase control vector (Promega,
Madison, WI,  USA). The GADD45 and C/EBP  expression plas-
mids have been described previously [6]. After incubation for 24 h,
cell extracts were analyzed for luciferase activity using the dual-
luciferase reporter assay system (Promega Corporation). Data are
expressed as means ± SD (error bars) of three independent experi-
ments.
The human GADD45  ˇ promoter construct pGL2-GADD45ˇ
(−1512/+232), previously described as GADD45  ˇ (−1594/+141) [8],
was used as a template for PCR generation of promoter mutants
using the following primer set: GADD45  ˇ (−1512/+232) forward,
5 /= -GAA GAT CTT TGC AAC CGC CAC GGT CCC CTT AT-3 /= ; and
reverse, 5 /= -CCC AAG CTT TGT TGC AAT TAT AAT CCA CAG TGG
ATG CG-3 /= (GLprimer2).
C/ebpˇ-haploinsufﬁcient mice
The Cebpˇtm1Vpo/J mouse strain (stock number 006873, Jackson
Laboratory, Bar Harbor, ME,  USA) carries a targeted mutation gen-
erated by replacing the C-terminal 72 amino acids of the encoded
protein, containing the leucine zipper and part of the basic domain,
with an MCI-Neo poly(A)+ cassette [28]. Articular cartilage sam-
ples were obtained from knee joints of 8-week-old C/ebpˇ+/− mice
(n = 3) and wild-type (WT) C57BL/6 controls (n = 3; Japan SLC, Inc.,
Shizuoka, Japan). Immunohistochemical analysis was  performed
using anti-GADD45  and anti-C/EBP antibodies, as described
previously [25]. Colocalization of anti-GADD45  and anti-C/EBP
immunoreactivity was  analyzed by CLSM. Histological studies were
performed at the site of the medial tibiofemoral joint, and counts of
C/EBP-  and GADD45-positive chondrocytes were recorded sep-
arately in the superﬁcial cartilage zones. Five regions of interest
(ROI) of 60-m deep and 100-m long were serially superimposed
over the immunostained sections. The superﬁcial cartilage was
deﬁned as the area from the cartilage surface to a depth of 60 m.
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mmunostained sections were digitized using a 20× microscope
bjective, using isotype-matched IgG negative controls to set back-
round levels. Three independent blinded observers counted the
umber of C/EBP  and GADD45 positive chondrocytes in the
elected ROIs.
eneration of cartilage oligomeric matrix protein (Comp)-driven
onditional C/EBPˇ-overexpressing transgenic mice
To investigate whether expression of the Gadd45  ˇ gene is
elated to that of C/EBP  in articular chondrocytes, we  gener-
ted transgenic mComp-tTA;pTRE-Tight-BI-DsRed-mC/ebp  ˇ mice, in
hich the tetracycline (Tet)-responsive transcriptional activator
tTA) is driven by the Comp promoter, and mC/ebp  ˇ by the Tet
esponse element (TRE). The inducible expression of mC/ebp  ˇ is
hus driven by the mComp promoter, employing a strategy similar
o that described by Xu et al. [29]. COMP is an oligomeric glycopro-
ein primarily expressed in developing and mature cartilage, as well
s in synovium, tendons, and ligaments. In a previous study involv-
ng generation of a Comp transgenic mouse, 1.7 kb of the human
OMP promoter was shown to be sufﬁcient to drive cartilage-
peciﬁc gene expression in vitro [30]. The genomic structures of
he 8.4-kb murine Comp and 8.0-kb human COMP are similar, and
lignment of their 5 /= ﬂanking ends has revealed high sequence
dentity [31]. In the present study, we generated transgenic mice
xpressing C/ebp  ˇ under the control of the mComp promoter using
he Tet-off inducible system, which was chosen to allow inducible
nd reversible gene expression [32–35]. For robust expression, the
Comp  promoter was used to drive a tTA gene extracted from the
Tet-off vector (Clontech, Mountain View, CA, USA) and subcloned
nto a pcDNA3.1 backbone. The transgenic construct mComp-tTA
onsisted of the mComp promoter, the non-coding exon and ﬁrst
ntron of the -actin gene, tTA cDNA, and three repeats of the SV40
olyadenylation signal. mC/ebp  ˇ gene expression was driven by
he TRE promoter, and TRE-driven DsRed was used as a reporter
ene for tTA activity. We  generated an expression vector carry-
ng cDNA encoding LAP (isoform b) of C/EBP,  which lacked the
ORF, such that translation could not be controlled by the uORF
36]. For the construction of pTRE-Tight-BI-DsRed-mC/ebpˇ,  a DNA
ragment (representing the entire cDNA sequence of mC/ebp  ˇ iso-
orm b/LAP; NM 001287738.1) was removed by digestion with NotI
nd HindIII from mC/ebpˇ/pcDNA3.1(−) [6] and ligated into pTRE-
ight-BI-DsRed. The mComp-tTA and pTRE-Tight-BI-DsRed-mC/ebpˇ
ransgenic constructs were linearized by restriction digest and
uriﬁed following agarose gel electrophoresis.
Transgenic DNA was injected into the pronuclei of fertilized
ingle-cell embryos from C57BL/6 mice. Surviving eggs were then
ransferred into pseudopregnant female mice. Transgenic founder
ice were identiﬁed by PCR ampliﬁcation of transgenes using the
ollowing primers: tTA forward, 5 /= -AGG GCA TCG GTA AAC ATC
G-3 /= and reverse, 5 /= -GGA CGA GCT CCA CTT AGA CG-3 /= ,
nd mC/ebp  ˇ forward, 5 /= -GGT GAT GTC CAG CTT GGA GT-3 /=
nd reverse, 5 /= -CCC CGT AAT GCA GAA GAA GA-3 /= . Transgenes
ere maintained on a C57BL/6 background and their copy numbers
ere determined by quantitative PCR. Transgenic founder lines
ere crossed to produce compound mutant offspring (F1), deﬁned
ere as double-transgenic (D-Tg) mice. These transgenic animals
ere administered 200 g/mL doxycycline (DOX; Sigma–Aldrich)
n drinking water until expression of the transgene was  required,
ith 5% (w/v) sucrose having been added to mask the bitter taste
37]. Tails from 14-day-old crossbred mice were harvested, from
hich genomic DNA was extracted for tTA and C/ebp  ˇ PCR geno-yping.
Primary chondrocytes were isolated from the articular cartilage
f 6-day-old mComp-tTA;pTRE-Tight-BI-DsRed-mC/ebpˇ  mice [27]
nd cultured until conﬂuence. Cells were cultured with or without and Practice 212 (2016) 302–309
DOX at a ﬁnal concentration of 1 g/mL for 24 h to conﬁrm the DOX-
dependent suppression of DsRed expression in the Tet-off system.
Cells were then lysed to analyze C/ebp  ˇ and Gadd45  ˇ mRNA and
protein expression, using total RNA extracts and western blotting,
respectively, as described below.
This study was carried out in strict accordance with the recom-
mendations given in the Guide for the Care and Use of Laboratory
Animals of Kagoshima University. The protocol used for animal
experiments was approved by the Institutional Animal Care and
Use Committee, Graduate School of Medical and Dental Sciences,
Kagoshima University (permit number MD14026). All surgery was
performed under general anesthesia, and every effort was made to
minimize pain and the number of animals used.
Quantitative real-time polymerase chain reaction (qRT-PCR)
For qRT-PCR analysis, total RNA was extracted from murine
primary chondrocytes isolated from mComp-tTA;pTRE-Tight-BI-
DsRed-mC/ebp  ˇ mice 48 h after cessation of DOX treatment.
Brieﬂy, total RNA was  DNase-treated and reverse transcribed
using oligo(dT) primers, according to the manufacturer’s instruc-
tions (Invitrogen, Carlsbad, CA, USA), and qRT-PCR reactions were
performed using SYBR Green on a MiniOpticon machine (both Bio-
Rad, Hercules, CA, USA). The comparative Ct (Ct) method was
employed to determine fold-changes in gene expression, using the
housekeeping gene Gapdh as an internal control. At least three con-
centrations of each sample were run in triplicate. The primer sets
ampliﬁed fragments between 150 and 200 bp. Primer sequences
were as follows: mC/ebpˇ: 5 /= -AGC TGC TCC ACC TTC TTC TG-
3 /= and 5 /= -CAA GCT GAG CGA CGA GTA CA-3 /= ; mGadd45ˇ:
5 /= -GGG GGA TTT TGC AAT CTT CTT-3 /= and 5 /= -GGA TCA GGG
TGA AGT GAA TCT-3 /= ; mGapdh: 5 /= -AAC TTT GGC ATT GTG GAA
GG-3 /= and 5 /= -ACA CAT TGG GGG TAG GAA CA-3 /= .
Western blot analysis
Brieﬂy, cells were lysed in NP40 lysis buffer containing
0.5% NP40, 10 mM Tris–HCl (pH 7.4), 150 mM NaCl, 3 mM
pAPMSF (Wako Chemicals, Kanagawa, Japan), 5 mg/mL  aprotinin
(Sigma–Aldrich), 2 mM  sodium orthovanadate (Wako Chemicals),
and 5 mM EDTA. Protein samples (20 g) were resolved by 4–15%
sodium dodecyl sulfate polyacrylamide gel electrophoresis before
being transferred to polyvinylidene ﬂuoride membranes and incu-
bated with a primary antibody against C/EBP (C-19, Santa Cruz
Biotechnology; 1:1000 dilution). -Tubulin (Santa Cruz Biotech-
nology; 1:1000 dilution) was  used as a loading control. Detection
was achieved using the enhanced chemiluminescence system
(Amersham Biosciences, Chalfont St Giles, UK), according to the
manufacturer’s instructions.
Statistical analysis
Data are presented as means ± SD (error bars) from at least three
independent experiments. Statistical tests, consisting of analysis of
variance followed by Student’s t-test for unpaired data, were car-
ried out using Microsoft Excel (Microsoft, Albuquerque, NM,  USA).
p-Values <0.05 were considered signiﬁcant.
Results
C/EBP  ˇ and GADD45  ˇ protein levels and localization in human
OA articular cartilageWe  examined the levels and localization of C/EBP and
GADD45 proteins by immunohistochemistry, using serial sections
of femoral head articular cartilage from ﬁve OA patients and three
H. Shimada et al. / Pathology – Research and Practice 212 (2016) 302–309 305
F oarthr
w  and 
c
t
m
c
w
e
r
c
T
c
t
G
G
+
e
a
c
D
l
e
l
W
c
Gig. 1. Colocalization of C/EBP  and GADD45 in articular chondrocytes from oste
ith  OA and stained with toluidine blue (A and D), or immunostained for C/EBP (B
ontrol subjects without the disease. Representative data showed
hat GADD45 immunostaining was present in all cells in nor-
al  cartilage, while strong signals were restricted to chondrocyte
lusters in OA cartilage (Fig. 1C and F). C/EBP  immunostaining
as weak in chondrocytes from normal cartilage (Fig. 1B). How-
ver, intense C/EBP staining colocalized with strong GADD45
eactivity in OA cartilage chondrocyte clusters (Fig. 1E and F). This
olocalization was also conﬁrmed by CLSM (Fig. 1G, H and I).
ranscription of GADD45  ˇ is regulated by C/EBPˇ  in
hondrocytes via its promoter
We  next investigated whether C/EBP  induces GADD45ˇ
ranscription using a luciferase reporter assay based on the pGL2-
ADD45 luciferase-reporter construct, containing 1.7 kb of the
ADD45  ˇ promoter sequence (spanning nucleotides −1512 to
232). Co-transfection experiments with an expression vector
ncoding C/EBP  showed upregulation of GADD45  ˇ promoter
ctivity, indicating that C/EBP  regulates GADD45 at the trans-
riptional level (Fig. 2).
ecreased C/EBP  ˇ expression is associated with lower GADD45ˇ
evels in mouse cartilage chondrocytes
To investigate the role of C/EBP  in the regulation of GADD45
xpression in vivo, we measured levels of the latter in articu-
ar chondrocytes from C/ebpˇ-haploinsufﬁcient mice (C/ebpˇ+/−).
e  observed decreased C/EBP immunostaining in C/ebpˇ+/− mice
ompared to their WT  counterparts (Fig. 3B and E). Importantly,
ADD45 immunostaining was also reduced in C/ebpˇ+/− animalsitis (OA) patients. Serial sections of articular cartilage were obtained from patients
E) or GADD45 (C and F). Original magniﬁcations were 40× (A–C) and 200× (D–F).
compared to WT  mice (Fig. 3C and F). Relative quantiﬁcation
of positive staining revealed these reductions to be signiﬁcant,
and demonstrated a positive correlation between C/EBP and
GADD45 protein levels.
Upregulation of Gadd45  ˇ transcription in Comp-expressing
chondrocytes from conditional C/ebpˇ-overexpressing transgenic
mice
To further conﬁrm the role of C/EBP  in the control of Gadd45ˇ
gene expression in articular cartilage in vivo, we generated two
transgenic mouse strains, mComp-tTA, as described by Xu et al. [29],
and pTRE-Tight-BI-DsRed-mC/ebpˇ.  Three different mComp-tTA and
two different pTRE-Tight-BI-DsRed-mC/ebpˇ  lines were established.
No gross abnormalities were observed in any of the transgenic mice,
and skeletal analysis showed the size of newborn transgenic and
WT mice to be similar (data not shown). mComp-tTA;pTRE-Tight-
BI-DsRed-mC/ebp  ˇ D-Tg mice were generated by crossing the two
lines. tTA and C/ebp  ˇ PCRs using genomic DNA from these crossbred
mice conﬁrmed the presence of both transgenes (Fig. 3A). Primary
chondrocytes derived from articular cartilage of mComp-tTA;pTRE-
Tight-BI-DsRed-mC/ebp  ˇ mice were cultured in the presence or
absence of DOX for 24 h. As shown in Fig. 4B, DOX treatment
reduced in vitro DsRed levels, indicating diminished expression of
the C/ebp  ˇ transgene. Moreover, both C/ebp  ˇ mRNA and C/EBP
protein levels in primary chondrocytes cultured without DOX were
signiﬁcantly higher than those in cells cultured in its presence
(Fig. 4C and D). Induction of C/ebp  ˇ mRNA expression in DOX-free
culture medium was  associated with increased Gadd45  ˇ mRNA lev-
els (Fig. 4D). Taken together, the results of our in vitro studies using
306 H. Shimada et al. / Pathology – Research and Practice 212 (2016) 302–309
Fig. 2. C/EBP regulates the GADD45  ˇ promoter responsive to synergistic induction by C/EBP and GADD45. ATDC5 cells were co-transfected with deletion mutants of the
GADD45ˇ  promoter (−1512/+232) and expression vectors encoding human C/EBP or GADD45, alone or in combination. Luciferase activity was  normalized to pRL-TK
reporter activity and is expressed as fold-induction compared to the empty vector control. Data are expressed as means ± SD (error bars) of three independent experiments.
Fig. 3. Decreased GADD45 expression in C/ebpˇ+/− mice. Hematoxylin and eosin staining (A and D) and immunostaining for C/EBP  (B and E) and GADD45 (C and F) in joint
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cartilage from C/ebpˇ+/− (D–F) or C57BL/6 wild-type mice (WT; A–C). Chondrocytes e
ice.  Bar = 200 m (A and D) and 30 m (B, C, E, and F). Percentages of C/EBP-  and G
o  WT  controls. Values are means ± SD. *p < 0.05.
romoter constructs and in vivo experiments with C/ebpˇ+/− mice
ndicate that Gadd45  ˇ gene expression is, at least in part, dependent
n C/ebpˇ.
iscussion
Early OA changes are associated with aberrant chondrocyte
ehavior and are characterized by the appearance of ﬁbrillation
nd cell clusters, activation of matrix-degrading enzymes such as
MP-1, -3, and -13, and changes in the quantity, distribution, and
omposition of matrix proteins [38]. Previously, using microarrayted stronger C/EBP and GADD45 staining in WT  controls than in haploinsufﬁcient
5-positive chondrocytes in C/ebpˇ+/− mice were signiﬁcantly decreased compared
data, we  revealed that GADD45  ˇ mRNA levels are elevated in early
OA cartilage, and reduced in late-stage specimens, suggesting that
GADD45 contributes to cartilage homeostasis and plays a role in
this disease [7]. In addition, immunohistochemical analysis showed
stronger GADD45 immunostaining in early OA chondrocytes com-
pared to late OA cartilage. However, strong staining was  observed
in chondrocyte clusters and osteophytes at all stages, suggesting
differential and site-speciﬁc transcriptional control of GADD45
in OA cartilage [7]. Together, these results suggest that GADD45
can modulate gene expression patterns related to phenotypic
changes in early OA and has prominent roles in the formation and
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Fig. 4. Establishment of transgenic mComp-tTA;pTRE-Tight-BI-DsRed-mC/ebp  ˇ mice overexpressing C/ebp  ˇ under control of the Comp promoter and Tet-off system. (A) tTA,
C/ebpb,  and Gapdh PCRs using genomic DNA from crossbred mice clearly demonstrated the presence of both transgenes. (B) mComp-tTA;pTRE-Tight-BI-DsRed-mC/ebp  ˇ primary
chondrocytes cultured with or without doxycycline (DOX) for 24 h showed decreased and increased DsRed staining, respectively, as visualized by ﬂuorescent microscopy
(400×  original magniﬁcation). (C) Western blotting of protein samples from wild-type (WT) and double-transgenic (D-Tg) mice with and without DOX  treatment revealed
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aintenance of cell clusters and osteophytes throughout progres-
ion of this disease.
Recent publications have revealed that C/EBP plays a part
n cartilage degeneration and remodeling. This protein regu-
ates the expression of matrix-degrading enzymes and Col10a1
39], and promotes chondrocyte transition from proliferation to
ypertrophic differentiation through transactivation of p57 [21].
urthermore, C/EBP-haploinsufﬁcient mice are resistant to car-
ilage destruction, inﬂammatory arthritis, and surgically induced
A, indicating the involvement of C/EBP  in cartilage destruction
uring OA progression [21,23,24].the absence of DOX. (D) Real-time PCR analysis of C/ebp  ˇ and Gadd45  ˇ expression
 C/ebp  ˇ mRNA levels in DOX-treated cultures, accompanied by elevated Gadd45ˇ
C/EBP and GADD45 share downstream targets and func-
tional outcomes in chondrocytes, and an interplay between these
molecules has been observed in the regulation of Col10a1 and
Mmp13 promoter activities [6]. Thus, it is conceivable that they
also interact in the pathogenesis of OA. Previously, we have shown
that GADD45 is important in OA progression, maintaining carti-
lage homeostasis and activating transcription factors of the C/EBP
and AP-1 families, as well as controlling the promoter activities of
genes encoding matrix-degrading enzymes, such as MMP13, and
collagens type II and X [6,7]. It is known that members of the AP-1
and C/EBP families act on functional binding sites of the GADD45
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romoter to activate GADD45 transcription via p38, JNK, or
anonical NF-B activation in tumor cells or inﬂammatory milieu
6,40–42]. Our previous reports showed that in response to BMP-2
reatment, RUNX2 enhances Gadd45  ˇ promoter activity in coop-
ration with SMAD1 [8], and that C/EBP-induced transcriptional
ctivation of the Mmp13 and Col10a1 promoters is augmented by
ADD45 [6].
C/EBP controls transcription by binding directly to DNA after
omo- or hetero-dimerization with other leucine zipper family
embers, and via complex formation with other co-activators or
eneral transcription factors. The activity of C/EBP  is determined
y transcriptional regulation and post-translational modiﬁcations,
uch as phosphorylation [9]. This suggests that other pathways
ight be involved in GADD45-enhanced C/EBP  activation at
he GADD45  ˇ promoter. This may  involve stabilization of com-
lex formation by direct binding of C/EBP  to the GADD45ˇ
romoter through an unidentiﬁed C/EBP-binding element, or
ndirect binding via other transcription factors. However, the
etailed mechanism controlling GADD45 expression in chondro-
ytes remains unknown, and the transcriptional control of this
rotein in chondrocytes merits further investigation.
Our results reveal an important physiological role for C/EBP
n the regulation of GADD45  ˇ gene expression in articular chon-
rocytes, and imply that the induction of GADD45 by C/EBP
nd subsequent activation of the latter by the former may  con-
titute a positive feedback loop in these cells, contributing to
artilage degradation and osteophyte formation in early OA. How-
ver, it is important to note that, while we successfully used
rimary chondrocytes isolated from D-Tg mice to conﬁrm the
nduction of GADD45 mRNA and protein in vitro, we  could not
ssess whether the Comp-driven C/ebp  overexpression leads to
ncreased GADD45 levels in vivo. The latter is in part due to the rel-
tively low activity of the mComp promoter, combined with the fact
hat the overexpressed and endogenous mC/ebp  ˇ cannot be dis-
inguished and that we only assessed mC/ebp  ˇ levels in vivo using
mmunohistochemical approaches, which are not sensitive enough
o detect relatively small changes in protein levels.  Thus, although
e did show the contribution of C/EBP  to the GADD45 levels in
ivo, using C/ebpˇ+/− mice (Fig. 3), additional studies are required
o conﬁrm the contribution and in vivo link between C/EBP over-
xpression and GADD45 levels in the pathogenesis of OA. While
n the current study we did not observe strong positive GADD45
mmunostaining in non-OA specimens, which is very likely due
o the limited amount of specimens available for this work, both
ADD45 and C/EBP  are physiologically expressed in human car-
ilage and upregulated in OA lesions [7,24]. These molecules are
lso physiologically expressed in WT  mice, as shown in Fig. 3, and
he contribution of C/EBP  in physiological expression of Gadd45ˇ
s evident by using C/ebpˇ+/− mice (Fig. 3). However, concomitant
xpression of GADD45 and C/EBP  may  not be sufﬁcient to trigger
A pathology, as indicated by the lack of OA-like features in the WT
ice (Fig. 3). The latter suggests that abnormal activation of signal-
ng cascades or the presence of interacting partners [24,43] may  be
equired for the GADD45/C/EBP axis to contribute to OA disease.
As an auto-acceleration system, the effect of C/EBP  on
he GADD45 promoter may  contribute to the regulation of
nﬂammation-related genes and matrix-degrading enzymes, such
s MMP13, or the abnormal expression of Col10a1 observed in OA.
ogether with our previous ﬁndings, the results described here
rovide new insight into the mechanisms leading to cartilage dam-
ge in the early stages of OA.onﬂicts of interest
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